The text discusses a comparative pharmacoeconomic study on the effectiveness and safety of dapagliflozin compared to sitagliptin in treating patients with type 2 diabetes. The purpose of the study is to determine the preferred treatment from a clinical and economic perspective and to evaluate the impact on budget using the drugs alogliptin and sitagliptin. Various studies have been conducted to compare the drugs, including a study on the addition of dapagliflozin to metformin therapy in patients with inadequate glycemic control. The study also compares the hypoglycemic activity of DPP-4 inhibitor sitagliptin and new GPR119 agonist ZB-16 in animals with type 2 diabetes. There is a significant amount of evidence on dapagliflozin's effectiveness in treating heart disease.